De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Chong Kun Dang Pharmaceutical Beheer
Beheer criteriumcontroles 1/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Young-Joo Kim
Algemeen directeur
n/a
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | 3.6yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 4.1yrs |
Recente managementupdates
Recent updates
Investors Aren't Buying Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Earnings
Sep 27
Does Chong Kun Dang Pharmaceutical (KRX:185750) Deserve A Spot On Your Watchlist?
Sep 08Are Investors Undervaluing Chong Kun Dang Pharmaceutical Corp. (KRX:185750) By 41%?
Jul 30Investors Don't See Light At End Of Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Tunnel
Jun 12Chong Kun Dang Pharmaceutical (KRX:185750) Seems To Use Debt Rather Sparingly
May 27A Look At The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Apr 09Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Apr 19Here's Why I Think Chong Kun Dang Pharmaceutical (KRX:185750) Is An Interesting Stock
Apr 05Declining Stock and Solid Fundamentals: Is The Market Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750)?
Mar 09Estimating The Fair Value Of Chong Kun Dang Pharmaceutical Corp. (KRX:185750)
Feb 24The Chong Kun Dang Pharmaceutical (KRX:185750) Share Price Is Up 112% And Shareholders Are Boasting About It
Feb 11Is Chong Kun Dang Pharmaceutical Corp. (KRX:185750) An Attractive Dividend Stock?
Jan 27
Does Chong Kun Dang Pharmaceutical (KRX:185750) Have A Healthy Balance Sheet?
Jan 12With EPS Growth And More, Chong Kun Dang Pharmaceutical (KRX:185750) Is Interesting
Dec 28What Kind Of Shareholders Hold The Majority In Chong Kun Dang Pharmaceutical Corp.'s (KRX:185750) Shares?
Dec 09Could The Market Be Wrong About Chong Kun Dang Pharmaceutical Corp. (KRX:185750) Given Its Attractive Financial Prospects?
Nov 24CEO
Young-Joo Kim
3.6yrs
Tenure
Mr. Young-Joo Kim serves as the President, Chief Executive Officer and Director of Chong Kun Dang Pharmaceutical Corp. and serves as its Chairman since March 26, 2021.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 3.6yrs | geen gegevens | geen gegevens | |
| Full-Time Auditor | 4.6yrs | geen gegevens | geen gegevens | |
| Independent Outside Director | 5.6yrs | geen gegevens | geen gegevens | |
| Director | less than a year | geen gegevens | geen gegevens |
4.1yrs
Gemiddelde duur
Ervaren bestuur: De raad van bestuur van A185750 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).